Clinically Advancing BDK Inhibitors

The physiopathology of cardiac and related disorders is strongly associated with BCAA metabolic imbalance. BDK, a negative regulator of the BCKDH complex, is significant in BCAA catabolic dysfunction. A Clinically potential BDK inhibitor, PF-07328948, with excellent drug-like properties, is under phase-1 clinical trials for CVD metabolic disorders.